Kiwi (Act d 2) IgE Test · Blood

If you have had an unexplained reaction to kiwi, or you have a history of pollen, latex, or fruit allergies, you may want to know which exact part of kiwi your immune system is reacting to. Act d 2 is one of several individual proteins in kiwi that can trigger an IgE response, and measuring antibodies to it can help clarify what is driving your symptoms.

This test detects IgE antibodies specifically targeted at Act d 2 (a kiwi protein in the thaumatin-like family). It is a research-grade marker used inside a broader kiwi component panel rather than a stand-alone diagnostic, and its result is most meaningful when read alongside your symptoms and the rest of your allergy workup.

What Act d 2 Actually Is

Act d 2 is one of about a dozen kiwi proteins known to provoke an allergic immune response. It belongs to a family of plant proteins called thaumatin-like proteins (TLPs), which show up in several fruits and can sometimes cross-react across foods. IgE is the antibody class your immune system produces when it has been sensitized to an allergen. Detecting IgE against Act d 2 in blood means your immune system has, at some point, recognized this specific protein as foreign.

Sensitization is not the same as allergy. You can carry IgE to Act d 2 without ever reacting to kiwi, which is one of the main reasons this marker is interpreted with caution. The blood test confirms that the antibody exists. Whether it causes symptoms depends on the rest of your immune picture and how your body responds when you actually eat kiwi.

What the Evidence Shows About Act d 2 Sensitization

In a large Italian study of 7,176 allergic patients, sensitization to thaumatin-like proteins (mostly Act d 2) was found in only 1.9% of the group. People with isolated Act d 2 sensitization typically had low antibody levels (averaging around 0.6 kUA/L) and minimal symptoms. Those who were co-sensitized to other plant proteins had higher Act d 2 IgE (averaging around 1.4 kUA/L) and more reactions, including oral allergy syndrome and food-dependent exercise-induced anaphylaxis.

When researchers tested whether Act d 2 IgE could predict the severity of a kiwi reaction, the marker performed poorly on its own. The discrimination score (ROC AUC, a measure of how well a test sorts people who will react from those who will not, where 0.5 is no better than a coin flip and 1.0 is perfect) was only 0.51 to 0.61. After adjusting for other factors, Act d 2 IgE was not independently linked to moderate or severe symptoms.

Cross-Reactivity and Related Allergies

Act d 2 is part of a network of related plant proteins, and reactions can sometimes spill across foods or other exposures. In a small study of 20 people with baker's asthma (an occupational allergy to flour), 35% also developed oral allergy syndrome to kiwi, and 43% of those kiwi-allergic individuals had detectable IgE to Act d 2. The cross-reactivity in this group was traced mainly to shared sugar tags on proteins and to a different kiwi protein (Act d 1), rather than Act d 2 itself.

If you have known sensitivities to pollen, latex, or other fruits, kiwi reactions are more common, and component testing can help unpack which proteins are actually driving symptoms.

Why Act d 2 Is Not Read Alone

Kiwi has at least five well-studied allergens (Act d 1 through Act d 5) plus several others, and they signal different things. Act d 1 (actinidin) tends to mark isolated, often more severe kiwi allergy. Act d 8 and Act d 9 mostly reflect pollen-related cross-reactivity. Act d 2 sits in between, more useful as part of a pattern than as a stand-alone signal.

A component-resolved diagnosis, which measures IgE to several kiwi proteins at once, raises sensitivity from 17% (with whole kiwi extract testing) up to 77% when the full panel is used. Act d 1 carries the most diagnostic weight; Act d 2 contributes context. In a small adult cohort, Act d 2 IgE had 0% sensitivity and 100% specificity for clinically reactive kiwi allergy, meaning most people who reacted to kiwi did not have detectable Act d 2 antibodies, but those who did almost certainly had a true sensitization.

Where Counterintuitive Findings Fit

It is reasonable to assume that a positive Act d 2 result means you are kiwi-allergic, but the evidence does not support that simple reading. Act d 2 is best thought of as a phenotype marker rather than a yes/no allergy verdict. Isolated low-level positivity often comes with no symptoms. Higher levels combined with antibodies to other plant proteins shift the meaning toward real-world risk. The result is not "good" or "bad" in isolation; it is one tile in a larger mosaic that includes your history, skin testing, other kiwi components, and, when needed, an oral food challenge.

Tracking Your Trend

Specific IgE results can shift over time as your immune system encounters or stops encountering an allergen, and as overall atopic disease evolves. A single Act d 2 reading is a snapshot. If you are working on managing kiwi reactions, watching for cross-reactive sensitivities, or simply curious whether your sensitization is stable, retesting at intervals is more informative than any single number.

A reasonable approach: get a baseline, then retest in roughly six to twelve months, especially if your symptoms change or if you are actively avoiding kiwi. Pair retesting with notes about real-world exposures and reactions; the combined picture is what guides decisions, not the antibody level by itself.

What to Do With an Unexpected Result

If your Act d 2 IgE is positive but you have never reacted to kiwi, this most often reflects silent sensitization rather than active allergy. It is worth ordering the rest of the kiwi component panel (Act d 1, Act d 5, Act d 8, Act d 9, Act d 10) to see whether you carry markers tied to more serious reactivity or pollen cross-reactivity. A skin prick-by-prick test with fresh kiwi often adds useful information, since it has higher sensitivity than blood testing alone.

If your result is positive and you have had symptoms after eating kiwi, an allergist (ideally one familiar with component-resolved diagnostics) is the right next step. Depending on the pattern, the workup may include a supervised oral food challenge, which remains the most reliable way to confirm or rule out true clinical allergy. If your result is negative but you have had clear reactions, do not stop avoiding kiwi based on this one test; the marker has low sensitivity in isolation.

When Results Can Be Misleading

• Cross-reactive sugar tags: some IgE responses are triggered by sugar molecules attached to plant proteins rather than by Act d 2 itself, which can produce a positive test without true clinical reactivity to kiwi.
• Low-level isolated positives: small amounts of Act d 2 IgE without sensitization to other plant proteins are often clinically silent, based on cohort data.
• Assay differences: different lab platforms (such as multiplex panels versus single-allergen assays) can produce different readings for the same person, so changing labs mid-tracking can muddy a trend.
• Recent allergen exposure or treatment: general allergy treatments and overall atopic activity can shift specific IgE levels over time; what looks like a change in kiwi sensitization may reflect broader immune shifts.